{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Defined as the highest dose tested in which none or only one patient experienced dose-limiting toxicity (DLT) attributable to the study drug(s), when 6 patients have been treated at that dose and are evaluable for toxicity.","groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"OG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"OG001","title":"Combination"}],"populationDescription":"Maximum tolerated dose data not available because this data was not collected","reportingStatus":"POSTED","timeFrame":"6 months","title":"Maximum Tolerated Dose of Pembrolizumab and Copanlisib","type":"SECONDARY"}